TXG Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
150.7M
-0.2%
151.0M
+0.1%
150.8M
-9.1%
166.0M
+11.4%
149.0M
Cost of Revenue
37.7M
-2.1%
38.5M
-13.7%
44.7M
-15.7%
53.0M
+8.8%
48.7M
Gross Profit
112.9M
+0.4%
112.5M
+6.0%
106.2M
-6.1%
113.0M
+12.7%
100.3M
Operating Expenses
129.0M
-2.3%
132.1M
+7.2%
123.2M
-7.1%
132.6M
+0.0%
132.5M
R&D
52.9M
-6.8%
56.8M
-0.1%
56.8M
+1.6%
56.0M
-2.1%
57.2M
SG&A
76.1M
-3.3%
78.7M
+18.5%
66.4M
-13.4%
76.6M
+1.7%
75.4M
Operating Income
-16057000
+17.9%
-19555000
-14.7%
-17046000
+12.8%
-19541000
+39.4%
-32242000
EBITDA
-6553000
+50.7%
-13291000
-87.5%
-7089000
+25.2%
-9476000
+56.8%
-21945000
Net Income
-19425000
-8.3%
-17931000
-33.1%
-13470000
+17.1%
-16252000
+40.8%
-27472000
EPS (Basic)
$-0.15
-7.1%
$-0.14
-40.0%
$-0.10
+23.1%
$-0.13
+40.9%
$-0.22
EPS (Diluted)
$-0.15
-7.1%
$-0.14
-40.0%
$-0.10
+23.1%
$-0.13
+40.9%
$-0.22
Shares (Diluted)
130.8M
+0.6%
130.0M
+1.3%
128.3M
+1.5%
126.4M
+0.7%
125.5M
10x Genomics (TXG) — Financials